Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.84 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.84 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.84 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.84 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL3477082 | 0.95 | OPRD1 (0.85) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL40753 | 0.94 | OPRD1 (0.84) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29623699 | 0.94 | OPRD1 (0.84) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL40754 | 0.94 | OPRD1 (0.84) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8374708 | 0.93 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL15055206 | 0.93 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL149700 | 0.93 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2443249 | 0.92 | OPRD1 (0.89) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL27547724 | 0.92 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.92 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414604-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2023-12-28 | — | — | US | claimed |
| US-20200345720-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2020-11-05 | — | — | US | claimed |
| US-20190167665-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2019-06-06 | — | — | US | claimed |
| EP-2123274-B1 | MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORING UNIT AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME | TEIKA PHARMACEUTICAL CO LTD (JP) | 2016-08-24 | — | — | EP | claimed |
| US-20160175297-A1 | Morphine Formulations | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2016-06-23 | — | — | US | claimed |
| US-9326979-B2 | Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same | TEIKA PHARMACEUTICAL CO., LTD. (JP) | 2016-05-03 | — | — | US | claimed |
| EP-2968132-A1 | INJECTABLE MORPHINE FORMULATIONS | Becton Dickinson France S.A.S (FR) | 2016-01-20 | — | — | EP | claimed |
| US-9192608-B2 | Morphine formulations | BECTON DICKINSON FRANCE S.A.S. (FR) | 2015-11-24 | — | — | US | claimed |
| US-20150246036-A1 | Morphine Formulations | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2015-09-03 | — | — | US | claimed |
| WO-2014140095-A1 | INJECTABLE MORPHINE FORMULATIONS | BECTON DICKINSON FRANCE S.A.S. (FR) | 2014-09-18 | — | — | WO | claimed |
| CN-104042565-A | Morphine formulations, kits comprising the same, and uses thereof | BECTON DICKINSON FRANCE SAS | 2014-09-17 | — | — | CN | claimed |
| CN-101621999-B | Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same | TEIKA PHARMACEUTICAL CO LTD JP | 2012-09-26 | — | — | CN | claimed |
| US-20100074943-A1 | MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORING UNIT AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME | TEIKA PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | claimed |
| CN-101621999-A | The transdermal formulation that percutaneous absorbs medical composition, medical composition storage element and utilized this storage element | TEIKA PHARMACEUTICAL CO LTD | 2010-01-06 | — | — | CN | claimed |
| EP-2123274-A1 | MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORING UNIT AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME | Teika Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | claimed |
| US-20250281680-A1 | DRUG-ELUTING SURGICAL ARTICLES AND RELATED METHODS | BIOSAPIEN INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250228846-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2025-07-17 | — | — | US | disclosed |
| US-5378474-A | Pellet having a core including at least one highly soluble active ingredient and a coating partially soluble at high acidity; opiod drugs | F. H. FAULDING & CO. LIMITED (AU) | 1995-01-03 | — | — | US | disclosed |
| US-5330766-A | Water soluble active ingredient core coated with matrix and enteric polymers; high speed, uniform release | F. H. FAULDING & CO. LIMITED (AU) | 1994-07-19 | — | — | US | disclosed |
| US-5202128-A | Oral administering | F. H. FAULDING & CO. LIMITED (AU) | 1993-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345720-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20190167665-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20250228846-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20230414604-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20150246036-A1 | Morphine Formulations | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20160175297-A1 | Morphine Formulations | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.